

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION

CONCLUSION OF STRATEGIC COOPERATION FRAMEWORK AGREEMENT

This announcement is made by the Company pursuant to Rule 13.09(2) of the Listing Rules and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 16 May 2018 (“**16 May Announcement**”) in relation to the proposed strategic cooperation framework agreement between the Company and Jiangxi Government (“**Strategic Cooperation Framework Agreement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the 16 May Announcement.

The board of directors hereby announce that Company and Jiangxi Government have entered into the Strategic Cooperation Framework Agreement to leverage on the strength of each side, consolidate resources and build stable strategic relationship and cooperation mechanism.

As part of the strategic cooperation, Jiangxi Government (Jiangxi SASAC) agreed to the strategic restructuring of Jiangzhong Group whereby the Company will acquire and subscribe for 51% or more of equity interest in Jiangzhong Group by payment of cash or contribution of assets. The restructuring plan and related matters are subject to completion of due diligence, audit and assessment.

The transactions contemplated under the Strategic Cooperation Framework Agreement are subject to conclusion of definitive transaction documents, obtaining various PRC governmental approvals and compliance with applicable laws, regulations and stock exchange rules (including Hong Kong Listing Rules and/or SSE Listing Rules). Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

For and on behalf of
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Hong Kong, 17 May 2018

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Chenyang and Ms. WANG Jing as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.